CL2019003275A1 - Derivados de pirimidina como moduladores del receptor de pge2. - Google Patents
Derivados de pirimidina como moduladores del receptor de pge2.Info
- Publication number
- CL2019003275A1 CL2019003275A1 CL2019003275A CL2019003275A CL2019003275A1 CL 2019003275 A1 CL2019003275 A1 CL 2019003275A1 CL 2019003275 A CL2019003275 A CL 2019003275A CL 2019003275 A CL2019003275 A CL 2019003275A CL 2019003275 A1 CL2019003275 A1 CL 2019003275A1
- Authority
- CL
- Chile
- Prior art keywords
- modulators
- pyrimidine derivatives
- pge2 receptor
- moduestors
- formula
- Prior art date
Links
- 102000008866 Prostaglandin E receptors Human genes 0.000 title 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 title 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 abstract 1
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical class C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
- 229960002986 dinoprostone Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A DERIVADOS DE FENILO DE FÓRMULA (I), DONDE LOS SUSTITUYENTES SON COMO SE DESCRIBEN EN LA DESCRIPCIÓN, Y SU USO EN EL TRATAMIENTO DEL CÁNCER. SE REFIERE ADEMÁS A DERIVADOS DE BENZOFURANO Y BENZOTIOFENO DE FÓRMULA (III) Y SU USO COMO PRODUCTOS FARMACÉUTICOS, SU PREPARACIÓN, Y SUS SALES FARMACÉUTICAMENTE ACEPTABLES, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN COMPUESTOS DE FÓRMULA (I), Y SU USO COMO MODULADORES DE LOS RECEPTORES EP2 Y/O EP4 DE LA PGE2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017062031 | 2017-05-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003275A1 true CL2019003275A1 (es) | 2020-05-04 |
Family
ID=62186480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019003275A CL2019003275A1 (es) | 2017-05-18 | 2019-11-15 | Derivados de pirimidina como moduladores del receptor de pge2. |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US11712438B2 (es) |
| EP (1) | EP3625222B1 (es) |
| JP (1) | JP7159214B2 (es) |
| KR (1) | KR102632028B1 (es) |
| CN (1) | CN110612296A (es) |
| AR (1) | AR111941A1 (es) |
| AU (1) | AU2018269666B2 (es) |
| BR (1) | BR112019024109A2 (es) |
| CA (1) | CA3060597A1 (es) |
| CL (1) | CL2019003275A1 (es) |
| CO (1) | CO2019010578A2 (es) |
| CR (1) | CR20190559A (es) |
| CY (1) | CY1124608T1 (es) |
| DK (1) | DK3625222T3 (es) |
| EA (1) | EA201992676A1 (es) |
| ES (1) | ES2893452T3 (es) |
| HR (1) | HRP20211533T1 (es) |
| HU (1) | HUE056080T2 (es) |
| IL (1) | IL270623B2 (es) |
| LT (1) | LT3625222T (es) |
| MA (1) | MA49126B1 (es) |
| MX (1) | MX388256B (es) |
| PE (1) | PE20191814A1 (es) |
| PH (1) | PH12019502563A1 (es) |
| PL (1) | PL3625222T3 (es) |
| PT (1) | PT3625222T (es) |
| RS (1) | RS62440B1 (es) |
| SG (1) | SG11201908729UA (es) |
| SI (1) | SI3625222T1 (es) |
| TW (1) | TWI765041B (es) |
| UA (1) | UA125123C2 (es) |
| WO (1) | WO2018210994A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| WO2019136320A1 (en) | 2018-01-05 | 2019-07-11 | Icahn School Of Medicine At Mount Sinai | Method of increasing proliferation of pancreatic beta cells, treatment method, and composition |
| US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN113543783A (zh) * | 2018-12-31 | 2021-10-22 | 西奈山伊坎医学院 | 激酶抑制剂化合物和组合物及使用方法 |
| WO2022102731A1 (ja) | 2020-11-13 | 2022-05-19 | 小野薬品工業株式会社 | Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療 |
| JP2024524981A (ja) | 2021-06-24 | 2024-07-09 | レザボア ニューロサイエンス，インコーポレイテッド | Ｅｐ２アンタゴニスト化合物 |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| CA2402099C (en) | 2000-03-24 | 2011-04-26 | Pharmagene Laboratories Ltd. | Methods for the treatment of primary headache disorders using prostanoid ep4 receptor antagonists, and assays for agents for such treatment |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| GB0031302D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
| GB0031295D0 (en) | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
| GB0103269D0 (en) | 2001-02-09 | 2001-03-28 | Glaxo Group Ltd | Napthalene derivatives |
| MXPA04009960A (es) | 2002-04-12 | 2004-12-13 | Pfizer | Compuestos de pirazol como agentes anti-inflamatorios y analgesicos. |
| WO2003086390A1 (en) | 2002-04-12 | 2003-10-23 | Pfizer Japan Inc. | Imidazole compounds as anti-inflammatory and analgesic agents |
| BR0311247A (pt) | 2002-05-23 | 2005-03-15 | Theratechnologies Inc | Peptìdeos antagonistas do receptor subtipo ep4 da prostaglandina e2 |
| JP5015586B2 (ja) | 2003-01-29 | 2012-08-29 | アステランド ユーケイ リミテッド | Ｅｐ４受容体アンタゴニスト |
| MXPA06002001A (es) | 2003-08-26 | 2006-06-20 | Teijin Pharma Ltd | Derivados pirrolopirimidinona. |
| RS20060143A (sr) | 2003-09-03 | 2008-06-05 | Pfizer Inc., | Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2 |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| GB0324269D0 (en) | 2003-10-16 | 2003-11-19 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| EA200601847A1 (ru) | 2004-05-04 | 2007-04-27 | Пфайзер Инк. | Замещённые метиларил- или гетероариламидные соединения |
| EP1756043B1 (en) | 2004-05-04 | 2009-07-01 | RaQualia Pharma Inc | Ortho substituted aryl or heteroaryl amide compounds |
| HN2005000795A (es) | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
| JP5289046B2 (ja) | 2005-05-19 | 2013-09-11 | メルク カナダ インコーポレイテッド | Ｅｐ４アンタゴニストとしてのキノリン誘導体 |
| WO2006128129A2 (en) | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| AR060403A1 (es) | 2006-04-12 | 2008-06-11 | Sanofi Aventis | Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2 |
| EP2013169B1 (en) | 2006-04-24 | 2012-08-22 | Merck Canada Inc. | Indole amide derivatives as ep4 receptor antagonists |
| CA2654811A1 (en) | 2006-06-12 | 2007-12-21 | Merck Frosst Canada Ltd. | Indoline amide derivatives as ep4 receptor ligands |
| US20080280891A1 (en) | 2006-06-27 | 2008-11-13 | Locus Pharmaceuticals, Inc. | Anti-cancer agents and uses thereof |
| WO2008008059A1 (en) | 2006-07-12 | 2008-01-17 | Locus Pharmaceuticals, Inc. | Anti-cancer agents ans uses thereof |
| KR101172936B1 (ko) | 2006-07-14 | 2012-08-16 | 노파르티스 아게 | Ａｌｋ-5 억제제로서의 피리미딘 유도체 |
| ES2421453T3 (es) | 2006-08-11 | 2013-09-02 | Merck Frosst Canada Ltd | Derivados de tiofenocarboxamida como ligandos del receptor EP4 |
| WO2008039882A1 (en) | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| EP2114877B1 (en) | 2007-02-26 | 2012-12-26 | Merck Canada Inc. | Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists |
| US8003661B2 (en) | 2007-03-26 | 2011-08-23 | Merck Canada Inc. | Naphthalene and quinoline sulfonylurea derivatives as EP4 receptor antagonists |
| CA2681861A1 (en) | 2007-03-26 | 2008-10-16 | Astellas Pharma Inc. | Ornithine derivative |
| EP2014657A1 (de) | 2007-06-21 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Diaminopyrimidine als Modulatoren des EP2-Rezeptors |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| SI2212297T1 (sl) | 2007-10-12 | 2011-09-30 | Ingenium Pharmaceuticals Gmbh | Inhibitorji protein kinaz |
| EP2254415B1 (en) | 2008-02-19 | 2013-01-23 | Janssen Pharmaceutica, N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| CN102026961B (zh) | 2008-05-14 | 2014-04-09 | 安斯泰来制药株式会社 | 酰胺化合物 |
| US20130225528A1 (en) | 2008-05-21 | 2013-08-29 | Ariad Pharmaceuticals, Inc. | Phosphorus Derivatives as Kinase Inhibitors |
| JP5536773B2 (ja) | 2008-08-14 | 2014-07-02 | ベータ・ファーマ・カナダ・インコーポレイテッド | Ｅｐ４受容体アンタゴニストとしてのヘテロ環式アミド誘導体 |
| CN102164942B (zh) | 2008-09-19 | 2017-02-15 | 生物科技研究有限公司 | 三萜系化合物及其使用的方法 |
| EP2346866B1 (en) | 2008-09-25 | 2013-11-27 | Merck Canada Inc. | Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| US8906914B2 (en) | 2009-08-18 | 2014-12-09 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid hydrolase |
| EP2504008A1 (en) | 2009-11-23 | 2012-10-03 | Lexicon Pharmaceuticals, Inc. | Methods and assays for the treatment of irritable bowel syndrome |
| EP2571867B1 (en) | 2010-05-21 | 2015-11-04 | Noviga Research AB | Novel pyrimidine derivatives |
| JP5956448B2 (ja) | 2010-09-21 | 2016-07-27 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| WO2012043634A1 (ja) | 2010-09-29 | 2012-04-05 | 株式会社エヌビィー健康研究所 | ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体 |
| EA201390717A1 (ru) | 2010-11-17 | 2013-10-30 | Новартис Аг | 3-(аминоарил)пиридиновые соединения |
| WO2012066065A1 (en) | 2010-11-17 | 2012-05-24 | Novartis Ag | Phenyl-heteroaryl amine compounds and their uses |
| EP2649061B1 (en) | 2010-12-10 | 2015-05-13 | Rottapharm Biotech S.r.l. | Pyridine amide derivatives as ep4 receptor antagonists |
| WO2012103071A2 (en) | 2011-01-25 | 2012-08-02 | Eisai R&D Management Co., Ltd. | Compounds and compositions |
| KR20140006048A (ko) | 2011-03-24 | 2014-01-15 | 케밀리아 에이비 | 신규한 피리미딘 유도체 |
| EP2702043A1 (en) | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibitors of inducible form of 6-phosphofructose-2-kinase |
| US9518044B2 (en) | 2011-06-20 | 2016-12-13 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| CA2839116C (en) | 2011-07-04 | 2019-07-16 | Rottapharm S.P.A. | Cyclic amine derivatives as ep4 receptor antagonists |
| EP2554662A1 (en) | 2011-08-05 | 2013-02-06 | M Maria Pia Cosma | Methods of treatment of retinal degeneration diseases |
| WO2013090552A1 (en) | 2011-12-13 | 2013-06-20 | Yale University | Compositions and methods for reducing ctl exhaustion |
| SMT202100158T1 (it) * | 2012-04-24 | 2021-05-07 | Vertex Pharma | Inibitori di dna-pk |
| TWI572597B (zh) | 2012-06-29 | 2017-03-01 | 美國禮來大藥廠 | 二甲基－苯甲酸化合物 |
| AR091429A1 (es) | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| EP2711364A1 (en) | 2012-09-21 | 2014-03-26 | Chemilia AB | 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer |
| MX373786B (es) | 2012-11-27 | 2020-03-23 | Thomas Helledays Stiftelse Foer Medicinsk Forskning | Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer. |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2765128A1 (en) | 2013-02-07 | 2014-08-13 | Almirall, S.A. | Substituted benzamides with activity towards EP4 receptors |
| TW201443004A (zh) | 2013-02-15 | 2014-11-16 | Lilly Co Eli | 苯氧基乙氧基化合物 |
| TWI636046B (zh) | 2013-05-17 | 2018-09-21 | 美國禮來大藥廠 | 苯氧基乙基二氫－１ｈ－異喹啉化合物 |
| EP3004082B1 (en) | 2013-05-30 | 2017-08-02 | Idorsia Pharmaceuticals Ltd | Cxcr7 receptor modulators |
| ES2669977T3 (es) | 2013-06-12 | 2018-05-29 | Kaken Pharmaceutical Co., Ltd. | Derivado de 4-alquinilimidazol y medicamento que lo comprende como ingrediente activo |
| EP3041822B1 (en) | 2013-09-04 | 2017-08-09 | Bristol-Myers Squibb Company | Compounds useful as immunomodulators |
| LT3041827T (lt) | 2013-09-06 | 2018-07-25 | Aurigene Discovery Technologies Limited | 1,2,4-oksadiazolo dariniai, kaip imunomoduliatoriai |
| WO2015044900A1 (en) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Therapeutic immunomodulating compounds |
| TR201807411T4 (tr) * | 2013-10-17 | 2018-06-21 | Vertex Pharma | DNA-PK inhibitörleri. |
| RS60426B1 (sr) | 2013-10-17 | 2020-07-31 | Vertex Pharma | Kokristali (s)-n-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)hinolin-4-karboksamida i njihovi deuterisani derivati kao inhibitori dnk-pk |
| AU2014366371B2 (en) | 2013-12-17 | 2017-02-16 | Eli Lilly And Company | Dimethylbenzoic acid compounds |
| DK3083562T3 (da) | 2013-12-17 | 2017-11-13 | Lilly Co Eli | Cykliske phenoxyethylaminderivater og deres aktivitet som EP4-receptormodulatorer |
| TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ｅｐ４配體之新穎苯并咪唑衍生物 |
| TW201623277A (zh) | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| US10052332B2 (en) | 2014-04-29 | 2018-08-21 | Emory University | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto |
| CN106572993B (zh) | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
| CA2948601A1 (en) | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
| PT3157916T (pt) | 2014-06-19 | 2019-03-25 | Ariad Pharma Inc | Compostos heteroarilo para inibição de cinase |
| WO2016021742A1 (en) | 2014-08-07 | 2016-02-11 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds as ep4 receptor antagonists |
| PT3243813T (pt) | 2015-01-09 | 2020-12-24 | Ono Pharmaceutical Co | Composto espiro tricíclico |
| CN108368127B (zh) | 2015-07-23 | 2020-12-11 | 武田药品工业株式会社 | 化合物及其作为ep4受体拮抗剂的用途 |
| CA3002144C (en) | 2015-10-16 | 2024-01-23 | Eisai R&D Management Co., Ltd. | Ep4 antagonists |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| WO2018013840A1 (en) | 2016-07-13 | 2018-01-18 | Vertex Pharmaceuticals Incorporated | Methods, compositions and kits for increasing genome editing efficiency |
| KR102612140B1 (ko) | 2017-05-18 | 2023-12-08 | 이도르시아 파마슈티컬스 리미티드 | 피리미딘 유도체 |
| PL3625228T3 (pl) | 2017-05-18 | 2021-12-20 | Idorsia Pharmaceuticals Ltd | Pochodne pirymidyny jako modulatory receptora pge2 |
| JP7065117B2 (ja) | 2017-05-18 | 2022-05-11 | イドーシア ファーマシューティカルズ リミテッド | Ｎ－置換インドール誘導体 |
| AR111807A1 (es) | 2017-05-18 | 2019-08-21 | Idorsia Pharmaceuticals Ltd | Derivados de benzofurano y benzotiofeno como moduladores del receptor pge2 |
-
2018
- 2018-05-17 HU HUE18725222A patent/HUE056080T2/hu unknown
- 2018-05-17 AR ARP180101315A patent/AR111941A1/es not_active Application Discontinuation
- 2018-05-17 CA CA3060597A patent/CA3060597A1/en active Pending
- 2018-05-17 ES ES18725222T patent/ES2893452T3/es active Active
- 2018-05-17 IL IL270623A patent/IL270623B2/en unknown
- 2018-05-17 CR CR20190559A patent/CR20190559A/es unknown
- 2018-05-17 MX MX2019013718A patent/MX388256B/es unknown
- 2018-05-17 RS RS20211256A patent/RS62440B1/sr unknown
- 2018-05-17 LT LTEPPCT/EP2018/062862T patent/LT3625222T/lt unknown
- 2018-05-17 EP EP18725222.6A patent/EP3625222B1/en active Active
- 2018-05-17 BR BR112019024109-4A patent/BR112019024109A2/pt not_active IP Right Cessation
- 2018-05-17 MA MA49126A patent/MA49126B1/fr unknown
- 2018-05-17 US US16/614,594 patent/US11712438B2/en active Active
- 2018-05-17 PE PE2019002396A patent/PE20191814A1/es unknown
- 2018-05-17 JP JP2019563491A patent/JP7159214B2/ja active Active
- 2018-05-17 SG SG11201908729U patent/SG11201908729UA/en unknown
- 2018-05-17 DK DK18725222.6T patent/DK3625222T3/da active
- 2018-05-17 PL PL18725222T patent/PL3625222T3/pl unknown
- 2018-05-17 EA EA201992676A patent/EA201992676A1/ru unknown
- 2018-05-17 KR KR1020197037298A patent/KR102632028B1/ko active Active
- 2018-05-17 PT PT18725222T patent/PT3625222T/pt unknown
- 2018-05-17 TW TW107116759A patent/TWI765041B/zh not_active IP Right Cessation
- 2018-05-17 CN CN201880031321.4A patent/CN110612296A/zh active Pending
- 2018-05-17 UA UAA201911975A patent/UA125123C2/uk unknown
- 2018-05-17 SI SI201830422T patent/SI3625222T1/sl unknown
- 2018-05-17 AU AU2018269666A patent/AU2018269666B2/en not_active Ceased
- 2018-05-17 HR HRP20211533TT patent/HRP20211533T1/hr unknown
- 2018-05-17 WO PCT/EP2018/062862 patent/WO2018210994A1/en not_active Ceased
-
2019
- 2019-09-27 CO CONC2019/0010578A patent/CO2019010578A2/es unknown
- 2019-11-15 CL CL2019003275A patent/CL2019003275A1/es unknown
- 2019-11-15 PH PH12019502563A patent/PH12019502563A1/en unknown
-
2021
- 2021-10-19 CY CY20211100906T patent/CY1124608T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003275A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2. | |
| CL2019003274A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2. | |
| CO2018002063A2 (es) | Análogos novedosos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
| CL2019000588A1 (es) | Compuestos y composiciones como inhibidores de los receptores endosomales tlr. | |
| DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
| DOP2017000151A (es) | Derivados de quinazolina utilizados para tratar el vih | |
| CL2019002297A1 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos. | |
| CL2018001325A1 (es) | Derivados de indol n-sustituidos como moduladores del receptor de pge2 | |
| CO2017012786A2 (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| MX2016011632A (es) | Derivados de azaspiro como antagonistas de trpm8. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| UY35818A (es) | Composiciones y métodos para modular los receptores x farnesoides | |
| MX2013006634A (es) | Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1. | |
| MX2019013639A (es) | Derivados de indol n-sustituidos. | |
| CR20170484A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| UY35906A (es) | Novedosos derivados de bencimidazol como ligandos de ep4 | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| CO2017009989A2 (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda | |
| ECSP11010807A (es) | Sales de los compuestos del inhibidor de vih | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| EA201791397A1 (ru) | СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| PE20180658A1 (es) | Sintesis total de shishijimicina a y sus analogos | |
| ECSP17046657A (es) | Síntesis total de trioxacarcina dc-45-a2 y preparación de análogos de trioxacarcina | |
| NI201600171A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1 |